Multiple Myeloma Market

View All

Phase 1b MonumenTAL-2 Study Result
TALVEY’s Versatility Shines: Key Insights from MonumenTAL-2 Study Illuminate Effective Strategies in Relapsed/Refractory Multiple Myeloma

Date of Abstract presentation11th December 2023IndicationsMultiple MyelomaAbstract Number1014Abstract typeOral TALVEY (talquetamab) is a bispecific T-cell engaging antibody designed to target the CD3 receptor found on T-cells and G protein-coupled receptor class C group 5 member D (GPRC5D). The findings presente...

Find More

Phase 3 Results Support D-VRd
DARZALEX FASPRO Quadruplet Regimen Demonstrates Striking Advancements in Treatment Outcomes for Newly Diagnosed Multiple Myeloma Eligible for Transplantation

Date of Abstract presentation12th December 2023IndicationsMultiple MyelomaAbstract NumberLBA1Abstract typeOral The PERSEUS study is being conducted in collaboration with the European Myeloma Network as a sponsor. PERSEUS is an ongoing, randomized, open-label, Phase III study comparing the efficacy and safety of ...

Find More

Phase 3 CARTITUDE-4 Study
Cilta-cel Demonstrates Prolonged and Deep Responses across Advanced Treatment Lines, Signifying Potential in Early Lenalidomide-Refractory Multiple Myeloma

Date of Abstract presentation11th December 2023IndicationsMultiple MyelomaAbstract Number1063Abstract typeOral According to the findings presented at the ASH 2023, the CARTITUDE-4 trial included a cohort of 419 patients. As of the clinical cut-off, 99 patients in the CARVYKTI arm and 66 in the standard of care (...

Find More

Phase 2 CARTITUDE-2 Trial of Ciltacabtagene Autoleucel
Cilta-Cel’s Prolonged Impact: Deep Responses and Safety Insights from Earlier Lines of Therapy in Multiple Myeloma

Date of Abstract presentation11th December 2023IndicationsMultiple MyelomaAbstract Number1021Abstract typeOral CARVYKTI (ciltacabtagene autoleucel) is a B-cell maturation antigen (BCMA)-directed, genetically modified autologous T-cell immunotherapy, which involves reprogramming a patient’s T cells with a transge...

Find More

bms-and-janssen-multiple-myeloma-treatment-drugs-landscape
BMS Vs. Janssen: Which Company Will Dominate The Multiple Myeloma Treatment Market This Decade?

Over the past several years, multiple myeloma treatment options have expanded widely for patients, resulting in significantly improved outcomes. The FDA approved around 16 new agents and 30 treatment regimens, transforming the multiple myeloma treatment paradigm for patients with newly diagnosed and relapsed/refrac...

Find More

cd38-directed-therapies-for-multiple-myeloma-treatment
Unleashing the Potential: CD38 Directed Therapies Revolutionize Multiple Myeloma Treatment

The landscape of multiple myeloma treatment has undergone a profound transformation with the advent of monoclonal antibodies (mAbs) targeting CD38. Among the notable breakthroughs, two anti-CD38 mAbs, DARZALEX (daratumumab) and SARCLISA (isatuximab-irfc), have been approved for clinical use. These groundbreaking mu...

Find More

bispecific-antibodies-for-multiple-myeloma-treatment
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray

Step aside, CAR-Ts; with three FDA approvals, the class of bispecific antibodies has begun to take on the relapsed/refractory multiple myeloma treatment segment. Currently, the US Food and Drug Administration (FDA) has authorized 10 bispecific antibodies and one bispecific molecule, the majority of which are a...

Find More

multiple-myeloma-treatment
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes

Multiple myeloma is the second most prevalent blood cancer diagnosis in the United States, after non-Hodgkin lymphoma. Males are significantly more likely than females to have multiple myeloma. Myeloma incidence is highly tied to age, with older adults having the highest incidence rates and being diagnosed most fre...

Find More

competitive-analysis-of-celmods-and-revlimid
CELMoDs – A Worthy Successor to REVLIMID?

Over the years, REVLIMID has become an integral weapon in the cancer therapeutics’ armory. This odyssey of REVLIMID in the multiple myeloma segment began in 2005, when it was approved by the US FDA for the treatment of adult patients with multiple myeloma, in combination with dexamethasone.  As the wise say...

Find More

Rare Cancer Market | Soft Tissue Sarcoma Market | Multiple Myeloma Market | Glioblastoma Multiforme Market | Cholangiocarcinoma Market | Synovial Sarcoma Market
Rare Cancer Market: A Global Crusade on what is a ‘less common cancer’?

Cancer is often challenging, however, diagnosis of rare cancer poses extra difficulties. Of all the diagnosed cancers, approximately 22% of the cases are rare cancers. According to the US National Cancer Institute, a cancer rare cancers as those with an incidence of fewer than 15 cases per 100 000 per year. Rare...

Find More